Yifan Pharmaceutical Co Ltd
002019
Company Profile
Business description
Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.
Contact
No. 50 Qinshan
Jincheng, Lin'an Economic Development Zone
HangzhouZhejiang311300
CHNT: +86 57163807806
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
4,098
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,273.84 | 11.68 | 0.14% |
| DAX 40 | 24,721.46 | 230.40 | 0.94% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,369.75 | 60.53 | 0.59% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |